Home » Stocks » KDMN

Kadmon Holdings, Inc. (KDMN)

Stock Price: $3.79 USD 0.13 (3.55%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $3.70 -0.09 (-2.38%) May 7, 5:46 PM
Market Cap 672.54M
Revenue (ttm) 2.12M
Net Income (ttm) -110.14M
Shares Out 171.69M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.79
Previous Close $3.66
Change ($) 0.13
Change (%) 3.55%
Day's Open 3.70
Day's Range 3.63 - 3.84
Day's Volume 977,847
52-Week Range 3.14 - 5.73

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and Mar...

2 days ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between Octob...

1 week ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and March 10, 2021...

1 week ago - Business Wire

Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - April 28, 2021) -  Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and c...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 27, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between Octob...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Kad...

1 week ago - Newsfile Corp

LOS ANGELES, April 21, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ("Kadmon" or "t...

2 weeks ago - PRNewsWire

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic...

2 weeks ago - Accesswire

NEW YORK, April 19, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and ...

2 weeks ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kadmon Holdings, Inc. (NASD...

3 weeks ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)-- #KDMNstock--The suit alleges defendants issued false statements concerning Kadmon business and prospects, resulting in its stock trading at inflated prices.

3 weeks ago - Business Wire

New York, New York--(Newsfile Corp. - April 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "C...

3 weeks ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States Dist...

3 weeks ago - Business Wire

New York, New York--(Newsfile Corp. - April 13, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Kadmon Holdings, In...

3 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 13, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities o...

3 weeks ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kadmon Holdings, Inc. (NASDAQ: KDMN) allegi...

3 weeks ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 13, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc...

3 weeks ago - Newsfile Corp

NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its of...

3 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Kad...

3 weeks ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company"...

3 weeks ago - Business Wire

New York, New York--(Newsfile Corp. - April 10, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and ce...

3 weeks ago - Newsfile Corp

NEW YORK, April 10, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kadmon Holdin...

3 weeks ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - April 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ...

4 weeks ago - Newsfile Corp

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, ALXN, AZN, BIIB, BNTX, CRSP ...
4 weeks ago - Investors Business Daily

Los Angeles, California--(Newsfile Corp. - April 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ...

1 month ago - Newsfile Corp

LOS ANGELES, April 7, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ("Kadmon" or "the...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 6, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kadmon Holdings, Inc. (NASDAQ: KDMN) allegi...

1 month ago - Newsfile Corp

SAN DIEGO & LORDSTOWN, Ohio--(BUSINESS WIRE)---- $KDMN #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Kadmon Holdings, Inc. (NASDAQ: KDMN) filed a class action compl...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $KDMN #KDMN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Kadmon Holdings, Inc.

1 month ago - Business Wire

NEW YORK, April 6, 2021 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or...

1 month ago - PRNewsWire

NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its off...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Kadm...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $KDMN #KDMN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Kadmon Holdings, Inc.

1 month ago - Business Wire

Atlanta, Georgia--(Newsfile Corp. - April 5, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Kadmon Holdings Inc. (NASDAQ: KDMN) ("...

1 month ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Kadmon Holdings, Inc. (NASD...

1 month ago - Business Wire

NEW YORK, April 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN) and certain of its off...

1 month ago - PRNewsWire

NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company'...

1 month ago - Accesswire

NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expa...

1 month ago - Accesswire

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Kadmon Holdings, Inc. ("Kadmon" or the "Company") (NASDAQ: KDMN). Such investors a...

1 month ago - Newsfile Corp

The FDA has extended the review period for Kadmon Holdings Inc's (NASDAQ: KDMN) marketing application seeking approval for belumosudil to treat chronic graft-versus-host disease (cGVHD). The goal date f...

1 month ago - Benzinga

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Applicat...

1 month ago - Accesswire

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 37.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended...

2 months ago - Accesswire

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1,...

2 months ago - Accesswire

NEW YORK and BEIJING, Feb. 23, 2021 /PRNewswire/ -- Graviton Bioscience Corporation ("Graviton"), a privately held early-stage drug development company founded by Dr. Samuel Waksal, and Beijing Tide Pha...

Other stocks mentioned: MGTX
2 months ago - PRNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: PAA, CBIO, RESN
2 months ago - 24/7 Wall Street

Steven Cohen ( Trades , Portfolio ) has revealed a large addition to his stake in Kadmon Holdings Inc. (NASDAQ:KDMN) according to GuruFocus' Real-Time Picks, a Premium feature.

3 months ago - GuruFocus

The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.

9 months ago - The Motley Fool

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Other stocks mentioned: BMY, PTGX
10 months ago - Investors Business Daily

About KDMN

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD... [Read more...]

Industry
Biotechnology
IPO Date
Jul 27, 2016
Stock Exchange
NASDAQ
Ticker Symbol
KDMN
Full Company Profile

Financial Performance

In 2020, KDMN's revenue was $8.29 million, an increase of 62.67% compared to the previous year's $5.10 million. Losses were -$108.91 million, 77.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for KDMN stock is "Strong Buy." The 12-month stock price forecast is 12.17, which is an increase of 221.11% from the latest price.

Price Target
$12.17
(221.11% upside)
Analyst Consensus: Strong Buy